I think there are at least 2 issues. A test to diagnose endo is a Big Deal for medical treatment - the patients, families and Drs know this. Whether or not it is a commercial success is a separate question - will PIQ be able to charge enough to recoup it's R&D nevertheless keep the company afloat - once a patient is diagnosed, they may not need more tests. . Although it's tempting to buy more shares on market, I'm waiting for the SPP as the $$$ goes to the company (whereas buying from current holders will not help the PIQ balance sheet). Let's hope PIQ has enough data & dollars to get this through the regulatory processes - TGA & FDA, implementation (sonic or other providers) and to reimbursement.
PIQ Price at posting:
74.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)